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Introduction: Esophageal adenocarcinomas (EAC) are aggressive 
cancers that are increasing in incidence and associated with a poor 
prognosis. The identification of highly expressed genes in EAC rela-
tive to metaplastic Barrett’s esophagus (BE) may provide new tar-
gets for novel early cancer detection strategies using endoscopically 
administered, fluorescently labeled peptides.
Methods: Gene expression analysis of BE and EACs were used to 
identify the cell surface marker transglutaminase 2 (TGM2) as over-
expressed in cancer. The expression of two major isoforms of TGM2 
was determined by qRT-polymerase chain reaction in an independent 
cohort of 128 EACs. Protein expression was confirmed by tissue 
microarrays and immunoblot analysis of EAC cell lines. TGM2 DNA 
copy number was assessed using single nucleotide polymorphism 
microarrays and confirmed by qPCR. TGM2 expression in neoadju-
vantly treated EACs and following small interfering RNA-mediated 
knockdown in cisplatin-treated EAC cells was used to determine its 
possible role in chemoresistance.
Results: TGM2 is overexpressed in 15 EACs relative to 26 BE 
samples. Overexpression of both TGM2 isoforms was confirmed 
in 128 EACs and associated with higher tumor stage, poor differ-
entiation, and increased inflammatory and desmoplastic response. 
Tissue microarrays and immunohistochemistry confirmed elevated 
TGM2 protein expression in EAC. Single nucleotide polymorphism 
and qPCR analysis revealed increased TGM2 gene copy number as 
one mechanism underlying elevated TGM2 expression. TGM2 was 
highly expressed in resistant EAC after patient treatment with neo-
adjuvant chemotherapy/radiation suggesting a role for TGM2 in 
chemoresistance.
Conclusion: TGM2 may be a useful cell surface biomarker for early 
detection of EAC.
Key Words: Esophageal adenocarcinoma, TGM2, Cell surface 
biomarker
(J Thorac Oncol. 2014;9: 872–881)
The incidence of esophageal adenocarcinoma (EAC) has increased rapidly in Western countries at a rate greater 
than most common cancers.1 This increase is thought to 
reflect a rise in obesity, chronic gastroesophageal reflux dis-
ease, and the development of the metaplastic condition termed 
Barrett’s esophagus (BE), where the normal esophageal squa-
mous epithelium is replaced by an intestinal-type columnar 
epithelium.2 Carcinomas arising at the gastroesophageal junc-
tion (GEJ) are also increasing although these do not seem 
to develop from Barrett’s metaplasia. Unfortunately, most 
patients are diagnosed with EAC or GEJ cancers at more 
advanced stages and when current treatments including che-
motherapy and radiation are less effective. When patients are 
diagnosed with either early stage cancer or the high-risk BE 
called high-grade dysplasia, surgical or endoscopically based 
interventions are associated with much more favorable patient 
outcomes.3 Current surveillance approaches for BE have 
limitations.4 As recently highlighted in a review by Vogelstein 
and colleagues,5 significant improvement in survival rates for 
cancer patients require the development of more effective 
approaches for early cancer detection. As a major advance in 
this direction, we have incorporated detection tools for EAC 
based on fluorescently labeled peptides directed against cell 
surface proteins highly expressed in EAC allowing for imag-
ing and early cancer detection with innovative noninvasive 
optical endoscopy.6
We have utilized expression profiling to examine genes 
that are overexpressed in EAC relative to Barrett’s metapla-
sia or dysplasia.7,8 Genes that are cell membrane targets or 
associated with the cell surface could provide important can-
didates for peptide-directed early cancer detection.9 Other 
strategies have incorporated fluorescent lectin molecules 
for the identification of dysplastic BE.10 As identified in the 
present study, tissue transglutaminase 2 (TGM2) is a highly 
expressed cell surface protein in EAC and a multifunctional 
molecule that can hydrolyze GTP and catalyze the covalent 
crosslinking of extracellular proteins.11 TGM2 is the most 
abundantly expressed member of the transglutaminase 
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family known to have two common isoforms and multiple 
alternatively spliced minor forms.12 Little is known regard-
ing TGM2 isoform function or their regulation;  however, 
alternative splicing seems to be an active process in cancer.13
TGM2 was recently reported to be overexpressed in 
esophageal squamous cell carcinomas, and it was suggested that 
it may function as a tumor growth suppressor when bound to 
the G-protein receptor GPR56,14 and a reduced interaction of 
the two is hypothesized to release cells from a quiescent state 
to a more metastatic state.15 In other epithelial cancers cell lines, 
expression of TGM2 has been linked to cisplatin and doxorubi-
cin drug resistance with knockdown of TGM2 causing increased 
chemosensitivity.16–18 TGM2 is also overexpressed in various 
primary tumors including lung,19 colon,20 ovarian,21 breast,6 and 
glioblastoma.22 The role of TGM2 and its various isoforms in 
these cancers may differ as to whether it induces apoptosis,23 cell 
proliferation,24 or chemoresistance,25–27 and the exact mecha-
nisms of TGM2 regulation is an area of intense investigation.28
In the present study, we have identified TGM2 as a possi-
ble cell surface marker for EAC that may be useful for its devel-
opment as a diagnostic marker. We measured the expression of 
the major isoforms of TGM2, validated its mRNA expression in 
an independent cohort of EACs and also examined TGM2 pro-
tein overexpression using tumor tissue microarrays (TMAs). 
We determined that the overexpression of TGM2 in EAC is in 
part because of gene amplification at 20q. In the neoadjuvant 
setting, EAC patients treated with chemotherapy and radiation 
do significantly worse when their cancers are still present at 
the time of surgery. We observe that these “resistant” EACs 
show increased expression of TGM2 at a frequency higher than 
those of untreated EACs, suggesting elevated TGM2 may be 
associated with reduced responsiveness to standard neoadju-
vant therapy and that TGM2 overexpression in EAC therefore 
may be useful as a potential marker for early cancer detection 
or an indicator for chemotherapeutic resistance.
MATERIALS AND METHODS
Cell Lines and Reagents
OE19 and OE33 EAC cell lines were obtained from Sigma-
Aldrich and cultured in RPMI media (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, 
Norcross, GA) and 1% antibiotic-antimycotic (GIBCO) at 37°C 
in a 5% CO
2
 atmosphere. Methyltransferase inhibitor 5′-aza-
2′-deoxycytidine (A3656, Sigma, St. Louis, MO) and histone 
deacetylation inhibitor trichostatin A (T8552, Sigma) were used 
as a 5 mM stock in DMSO and stored at −20°C. Cisplatin (P4394, 
Sigma) made as a 5 mM stock in phosphate-buffered saline 
was used immediately. Transforming growth factor β (100–21, 
PeproTech, Rocky Hill, NJ) stock was dissolved in 10 mM cit-
ric acid, pH 3.0, at a 10 ng/μL stock and stored at −80°C. Cell 
lines were genotyped for authenticity using the Identifiler Plus 
kit (Applied Biosystems, Grand Island, NY) at the University of 
Michigan DNA sequencing core facility (P01 HL057346).
Patients and Samples
Patient written consent was obtained and the study 
received approval from the University of Michigan Medical 
School Institutional Review Board. One-hundred and 
twenty-eight patients used in this study did not receive pre-
operative radiation or chemotherapy. Tissues were obtained 
from patients undergoing esophagectomy for cancer or high-
grade dysplasia (HGD) at the University of Michigan Health 
System. Twenty-one patients who had been treated with neo-
adjuvant chemotherapy (cisplatin and 5-fluorouracil or car-
boplatin and paclitaxel) and radiotherapy (50.4 Gy) followed 
by esophagectomy were examined as a subgroup of chemo-
resistant EAC. These tumors were confirmed by pathological 
assessment to contain significant amounts of viable tumor 
at the time of resection. National Comprehensive Cancer 
Network (NCCN) clinical practice guidelines were followed. 
These patients were less than 75 years old without other 
contraindications with T2 (invasion into the muscularis) or 
greater or positive nodal disease (N1 or greater) and treated 
with neoadjuvant chemoradiation. All tissues were collected 
immediately after surgery, quick-frozen in liquid nitrogen 
and stored at −80°C until use. BE with and without dysplasia 
and all tumor samples were cryostat sectioned and regions 
containing greater than 70% tumor or Barrett’s cell content 
were used for mRNA or protein isolation. Tumor and preneo-
plastic lesion characteristics were determined from pathol-
ogy reports performed by a board-certified pathologist.
RNA Extraction and Oligonucleotide Microarray
Total RNA was isolated from 15 EACs and Barrett’s 
metaplasia samples (13 non-dysplastic Barrett’s mucosa, 
six low-grade dysplasia (LGD), and seven high-grade 
dysplastic samples) using Trizol (Invitrogen) followed by 
RNeasy column purification (Qiagen, Germantown, MD), 
cRNA generation and hybridization to U133A GeneChips 
(Affymetrix, Santa Clara, CA). Data have been deposited 
in GEO (GSE37203).8 Hybridizations and array image 
analysis was performed by the University of Michigan DNA 
Microarray Core Facility. A filtering algorithm was used to 
select genes with either increased or decreased expression 
in adenocarcinomas or dysplastic BE when compared with 
BE samples. A twofold change in gene expression was con-
sidered significant.29 To normalize the microarray data, a 
summary statistic was calculated using the robust multichip 
average method30 as implemented in the Affymetrix library 
of the Bioconductor version 1.3 that provides background 
adjustment, quantile normalization, and summarization. 
Expression values for each sample were then compared with 
the mean expression value for the seven Barrett’s metaplasia 
samples.
Real-Time Reverse-Transcriptase Polymerase 
Chain Reaction (RT-PCR) Analysis
Real-time RT-PCR was performed on cDNA isolated 
from EAC, BE, and normal gastric or esophageal mucosa 
samples using either the 96-well StepOne Plus or 384-well 
7900HT Systems (Applied Biosystems) and the Platinum 
SYBR Green kit (Invitrogen). All primers were designed using 
NCBI Primer-BLAST and the primer sequences for TGM2 are: 
TGM2 all isoforms, forward CCAACTACAACTCGGCCCAT, 
and reverse CTGGTCATCCACGACTCCAC targeting 
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between exons 7 and 8; long isoform (NCBI NM_004613), 
forward GCAGGGGAGGAAGTTAAGGTGAGAA, and 
reverse GGCGGGGCCAATGATGACA targeting exon 
13; common short isoform (NCBI NM_198951), for-
ward GGTAAAGCCCTGTGTTCCTG, and reverse 
AGCGCCATGTAAGTGTCTGTG targeting its unique por-
tion in exon 10. Genomic primers for TGM2 are for intron 
2 forward GTGGCCGGGCTGGGATGG and reverse 
AAGGTGGGGTCGGGGTTTGAGG and for intron 11 for-
ward ATCCTTATCATCGCCATCATCATCATTATA and 
reverse ACTGCCGCTCCCTCTGCTGTTTA. Annealing 
temperatures were determined and optimized using Cepheid 
SmartCycler (Cepheid, Anaheim, CA). Expression values and 
copy number changes were determined by the 2-∆∆Ct algorithm.31 
Reference genes (GAPDH and ACTB) were applied to normal-
ize the 2-∆∆Ct calculation of Ct values of each target gene.
Single Nucleotide Polymorphism 
(SNP) Array Analyses
SNP arrays were performed as previously described.32 
Briefly, 73 EAC DNAs were genotyped using the Genome-
Wide Human Sty I 250K SNP Array (Affymetrix). Copy num-
ber analyses with SNP arrays were performed as a log
2
 copy 
number ratio exceeding 0.848 for amplifications and −0.737 
for deletions. Genomic positions were mapped in the hg18 
genome build. SNP data were visualized using the software 
IGV 1.3.1 (Integrative Genomics Viewer, www.broadinstitute.
org/igv).
Cell Proliferation Assays
Cell proliferation and viability were assessed using 
Cell Proliferation Reagent WST-1 according to the manufac-
turer’s instructions (Roche, San Francisco, CA). Cells were 
plated at low seeding density in quadruplicate in 96-well 
plates and allowed to adhere for 24 hours before treatment. 
Cell proliferation and viability were quantitated with ELx808 
Absorbance Microplate Reader (BioTek Instruments, Inc., 
Winooski, VT) at 450 nm with a reference wavelength at 
630 nm. T
0
 readings were taken 24 hours after cells were 
plated. Data were collected in triplicate or quadruplicate.
Small Interfering RNA (siRNA) Transfection
The SMARTpool: ON-TARGETplus siRNA targeting 
TGM2 at the open reading frame of both the long and short 
forms, accession NM_004613 and NM_198951, respectively, 
were obtained from Dharmacon (L-004971). siRNAs were 
transfected at 10–20 pM using the Lipofectamine RNAiMAX 
Reagent (Invitrogen). A nontargeting siRNA carrying the 
ON-TARGET modification (D-001810-01-20, Dharmacon, 
Lafayette, CO) was used as a control.
Immunohistochemistry of TMA
TMAs were constructed as previously described,33 and 
slides hybridized with monoclonal TGM2 Ab-1 (CUB7402, 
NeoMarkers) antibody at a 1:50–100 dilution after microwave 
citric acid epitope retrieval. Slides were lightly counterstained 
with hematoxylin, dehydrated, and cover slipped. Each sample 
was then scored 0, 1, 2, or 3 corresponding to absent, light, 
moderate, or intense staining by two individual readers.
Western Blot Analysis
Protein samples (10–40 µg) were resolved on Tris-
Glycine Gels (Invitrogen) and blotted to PVDF membranes 
(Millipore, Billerica, MA). TGM2 (CUB7402, NeoMarkers, 
Fremont, CA) or PARP (9542S, Cell Signaling, Danvers, MA) 
antibodies at a 1:5000 dilution were hybridized at 4°C over-
night. Anti-mouse (1010-05, Southern Biotech) or anti-rabbit 
(PI-1000, Vector, Burlingame, CA) secondary antibodies were 
used at 1:10,000 dilution and hybridized for 1 hour at room 
temperature. Western blot membranes were stripped for rehy-
bridization with β-actin (AB6276, Abcam, Cambridge, MA) 
at a 1:10,000 dilution for loading control.
Statistical Analyses
Differences in tissue TGM2 expression, tabulated by 
clinical and pathological characteristics were analyzed using 
the Fisher’s exact and χ2 test. Student’s t test and analysis 
of variance were used for comparing quantitative variables 
among two groups, with p < 0.05 considered statistically sig-
nificant. Overall survival was measured from the date of sur-
gery to the time of death or censoring at 5 years. Survival 
curves were constructed using the method of Kaplan-Meier 
and survival differences were calculated using the log-rank 
rest. The IBM SPSS Statistics 21.0 software was used for all 
statistical analyses.
RESULTS
TGM2 Is Highly Overexpressed 
in EAC Relative to BE
Cell surface targets overexpressed in EAC relative to the 
BE have significant potential for use in peptide-directed endo-
scopic early cancer detection strategies.6 Using a panel of 41 
available mRNA specimens from patients representing non-
dysplastic BE, LGD, HGD, and EAC, gene expression analy-
ses were performed to identify selectively overexpressed cell 
surface candidates. TGM2 gene was found significantly over-
expressed in EAC relative to non-dysplastic BE samples (t test 
p = 0.00025; Fig. 1A). To validate these array-based analy-
ses, real-time qRT-PCR was performed using the cDNA from 
the same 41 samples and TGM2-specific primers. Consistent 
results were obtained showing that EACs have significantly 
higher TGM2 expression relative to non-dysplastic BE, LGD, 
and HGD (analysis of variance p = 0.001 in Fig. 1A and p = 
0.003 in Figure 1B. High-level expression of TGM2 was also 
confirmed in one sample of HGD. Our observation of highly 
elevated TGM2 in EAC is consistent with previous transcrip-
tome-based analysis of these tumors.34–36
TGM2 mRNA Isoform Expression in EAC
There are two major TGM2 isoforms, a long form 
(NM_004613) containing 3937 base pairs (687AA) and 
the shorter form (NM_198951) truncated at the 3′UTR and 
containing only 1879 base pairs (548AA) with a unique 
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C-terminus.37 Previous work suggested that the short TGM2 
form lacks the residual GTP-binding and carboxy-terminal 
portion necessary for recognition and binding to phospholipase 
C and is proapoptotic, whereas the long TGM2 form correlates 
more with increased cell survival.23 Because the expression 
arrays used do not differentiate between the long and short 
TGM2 isoforms, we examined the expression of both isoforms 
in an independent and larger cohort, 128 EAC tumors, which 
also served as our validation cohort. Both TGM2 isoforms are 
expressed in EAC with the frequency of the TGM2 short and 
long forms in tumors having greater than or equal to twofold 
gene expression, 70.3% and 57%, respectively (Fig. 1C). The 
expression values of these two isoforms are significantly cor-
related (Pearson’s r = 0.5826, p < 0.001; Fig. 1D).
We then examined whether TGM2 isoforms correlate 
with patient survival or other clinical pathological variables 
including tumor stage and location (tubular esophagus or GEJ) 
in this cohort of 128 patients. A total of 128 patients were 
examined in this analysis with adenocarcinomas in the esoph-
agus and GEJ locations both included. A significant associa-
tion was found between higher TGM2 long isoform mRNA 
expression and disease stage (p = 0.019) and differentiation 
(p = 0.001). Tumors with greater inflammatory response had 
increased expression of both TGM2 isoforms (p = 0.001 long, 
and p = 0.01 short). There was also an association of increased 
TGM2 long expression with tumors showing greater desmo-
plastic response (p = 0.012) that was not seen with the short 
form (Table 1). Kaplan-Meier analysis of both TGM2 iso-
forms did not reveal a significant association of TGM2 mRNA 
expression with patient survival (Supplementary Figure 1, 
SDC 1, http://links.lww.com/JTO/A609). No other clinical 
features were found to be significantly associated with TGM2 
expression. The frequency of TGM2 expression in adenocarci-
nomas at the GEJ without BE and EACs associated with both 
seems similar in particular for the short isoform (p = 0.38, 
Table 1).
FIGURE 1.  Expression of TGM2 during progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC) and 
abundance of its long and short isoforms. A, Box plot of TGM2 mRNA expression levels (probe 201042_at; Affymetrix U133A) 
in BE, low-grade dysplasia, high-grade dysplasia, and EAC. TGM2 expression is significantly higher in EAC relative to BE samples 
(Student’s t test [p < 0.001; analysis of variance p = 0.001]). (B) Validation of TGM2 expression by qRT-PCR of the same samples 
shown in Figure 1A. The y-axis represents normalized expression to BE using the 2-∆∆Ct algorithm and shows that TGM2 expres-
sion is significantly higher in EAC (Student’s t test p = 0.009; analysis of variance p = 0.003). Outlier samples are marked with 
an open circle. (C) qRT-PCR of the expression of the long (black) and short (gray) isoforms of TGM2 in 128 EACs normalized to 
normal esophagus and stomach mucosa using the 2-∆∆Ct algorithm. The frequency of EAC expressing the TGM2 short and long 
isoforms greater than twofold is 70.3% and 57%, respectively. (D) The correlation coefficient between tumors expressing both 
isoforms r = 0.5826 and p > 0.001.
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TGM2 Protein Expression in EACs
TMAs of Barrett’s metaplasia and EAC samples were 
evaluated immunohistochemically using an anti-TGM2 anti-
body (Fig. 2). Staining of TGM2 was found to be absent in nor-
mal esophageal mucosa (Fig. 2A), less abundant in BE (Fig. 
2B), and more abundant in EAC samples (Fig. 2C, D). TGM2 
is reported to act by increasing the supply of growth factors 
at the cell surface24 and some tumors demonstrated membrane 
staining of TGM2 yet most showed abundant cytoplasmic 
localization of this protein. TGM2 expression within the under-
lying stroma was also observed in some tissues (Fig. 2B). The 
TMA-based analyses of TGM2 protein expression revealed 15 
EAC with high (23%), 40 with low (61%), and 10 (15%) show-
ing no expression. The abundance in EAC may relate to cell 
mobility as indicated by the DAVID terms that correlated with 
high TGM2 expressing EACs (Supplementary Table 1, SDC 
2, http://links.lww.com/JTO/A610). The most intense TGM2 
staining was observed in poorly differentiated tumors, consis-
tent with the mRNA analyses within this cohort (Table 1).
Regulation of TGM2
To determine the basis for elevated TGM2 expression, we 
examined whether this gene may be influenced by epigenetic 
regulation. In breast cancer and in non–small-cell lung cancers, 
TGM2 promoter hypermethylation seem to influence TGM2 
expression and chemosensitivity.19,38 In neuroblastoma cells, 
treatment with a histone deacetylase inhibitor increased expres-
sion of both the short and long isoforms of TGM2, rendering 
them more resistant to chemotherapy treatment.39 We therefore 
treated OE19 and OE33 EAC cell lines with the methylation 
and histone deacetylase inhibitors, 5-aza-2-deoxycytidine and 
trichostatin A, respectively, and examined their effect on TGM2 
TABLE 1.  Clinical Characteristics of EACs and TGM2 Isoform Expression
 TGM2 Long 
Overexpression
 TGM2 Short 
Overexpression
Low High p Low High p
Variables n = 128 n = 38 n = 90 n = 55 n = 73
Age (year)
  Range 25–89 46–85 25–89
ns
45–84 25–89
ns
  Median (Standard Deviation) 70 ± 10.6 70 ± 9 70 ± 11 69 ± 9 70 ± 12
Life Status n (%)
  Dead 96 (75%) 26 (27%) 70 (73%)
ns
42 (44%) 54 (56%)
ns
  Alive 32 (25%) 12 (38%) 20 (62%) 13 (41%) 19 (59%)
Gender n (%)
  F 22 (17%) 5 (22%) 17 (78%)
ns
4 (18%) 18 (82%)
0.01
  M 106 (83%) 33 (31%) 73 (69%) 51 (48%) 55 (52%)
Stage n (%)
  Low (I or II) 46 (36%) 14 (30%) 32 (70%)
0.019
19 (41%) 27 (59%)
ns
  High (III or IV) 82 (64%) 24 (29%) 58 (71%) 36 (44%) 46 (56%)
Differentiation n (%)
  Well 15 (12%) 10 (67%) 5 (33%)
0.001
9 (60%) 6 (40%)
ns  Moderate 45 (35%) 15 (33%) 30 (67%) 20 (44%) 25 (56%)
  Poor 68 (53%) 13 (19%) 55 (81%) 26 (38%) 42 (62%)
Inflammatory response n (%)
  High 46 (36%) 6 (13%) 40 (87%)
0.001
12 (26%) 34 (74%)
0.01  Moderate 44 (34%) 13 (30%) 31 (70%) 21 (48%) 23 (52%)
  Low 38 (30%) 19 (50%) 19 (50%) 22 (58%) 16 (42%)
Desmoplastic response, n (%)
  High 50 (39%) 9 (18%) 41 (82%)
0.012
16 (32%) 34 (68%)
ns  Moderate 37 (29%) 10 (27%) 27 (73%) 17 (46%) 20 (54%)
  Low 41 (32%) 19 (46%) 22 (54%) 22 (54%) 19 (46%)
EAC type, n (%)
  Barrett’s 44 (34%) 13 (30%) 31 (70%)
ns
25 (57%) 19 (43%)
0.038
  Single Nucleotide Polymorphism 64 (50%) 17 (27%) 47 (73%) 20 (31%) 44 (69%)
  Both 6 (4%) 4 (67%) 2 (33%) 4 (67%) 2 (33%)
  Other 14 (12%) 4 (29%) 10 (71%) 6 (43%) 8 (57%)
Clinical variables and TGM2 expression were evaluated in 128 EACs. Associations of twofold or greater expression of the long or short TGM2 isoforms were analyzed by Fisher 
or Pearson χ2 analyses. Each comparison is labeled either as significant (p value) or not significant (ns).
EAC, esophageal adenocarcinoma.
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mRNA expression using qRT-PCR. A modest increase in TGM2 
expression was observed only in OE19 that expresses low lev-
els of TGM2 endogenously (Supplementary Figure 2, SDC 1, 
http://links.lww.com/JTO/A609), suggesting that promoter 
hypermethylation might play a role in transcriptional regulation 
of TGM2. Our group has also recently examined significantly 
mutated genes in a cohort of 145 EACs using genome and 
exome sequencing.40 TGM2 was not mutated in these tumors 
and is thus not a likely mechanism for TGM2 overexpression.
Observing no robust epigenetic mechanism for elevated 
TGM2 expression, we next examined whether TGM2 may be 
regulated by factors that increase its transcription. With the sug-
gested positive feedback loop between TGFβ and TGM2 and 
because of a TGFβ binding region-900 upstream of the TGM2 
promoter,41 we examined whether exogenously added TGFβ 
could induce TGM2 expression in the EAC cell lines. Treatment 
with low doses of TGFβ significantly increased TGM2 expres-
sion of both isoforms in OE19 cells that have low expression 
of endogenous TGM2 (Supplementary Figure 3, SDC 1, http://
links.lww.com/JTO/A609). We did not observe any significant 
increase in TGM2 expression in similarly treated OE33 cells, 
which have higher baseline expression of TGM2 (Supplementary 
Figure 3, SDC 1, http://links.lww.com/JTO/A609). Treatment 
with 10% fetal bovine serum also increased TGM2 expression 
in these cells suggesting that potentially other transcription fac-
tors or mechanisms can also increase the expression of this gene.
TGM2 Overexpression in EAC and Copy 
Number Changes in Chromosome 20
We next examined copy number alterations in EAC 
using SNP microarrays.32,42 An integrative genomic analysis 
of 73 EACs revealed that the chromosome 20q12 region 
where TGM2 gene is located demonstrates increased DNA 
copy number in a subgroup of EAC consistent with gene 
amplification (Fig. 3A). Indeed, much of the 20q chromo-
somal arm seems to be amplified (Fig. 3B) having a value ≥ 
1.8 and representing greater than 4N of the haploid genome. 
Using this cutpoint, approximately 22% of the 73 EAC show 
TGM2 gene amplification (Fig. 3C). To validate these results, 
TGM2 copy number was examined in 52 of the 73 EAC 
patients having available DNA and subjected to quantita-
tive PCR using genomic primers for both introns 2 and 11 
of TGM2. These analyses confirmed that TGM2 DNA was 
amplified with a frequency of 15% for intron 2 and 11.5% for 
intron 11 (Fig. 3D,E) with an average of 13.4% and thus con-
sistent with the SNP array-derived frequency. The data sug-
gest that increased TGM2 copy number partially accounts for, 
in addition to epigenetic and TGFβ regulation, upregulated 
expression of TGM2.
TGM2 Expression During Neoadjuvant Therapy
Because of the reported influence of TGM2 expres-
sion in various cancer cell lines on chemoresistance,16,37 we 
examined TGM2 expression in a subset of 21 patients who 
had received preoperative chemotherapy, concurrent radiation 
therapy and subsequent esophagectomy, and whose tumors 
demonstrated minimal to no treatment response. TGM2 
mRNA expression of this cohort was examined using qRT-
PCR and compared with TGM2 expression from both normal 
esophagus (negative control) and EAC tumors with known 
TGM2 amplification (positive control) obtained from patients 
who had not received any chemotherapy or radiation therapy 
FIGURE 2.  Increased TGM2 pro-
tein expression in EACs. Sections of 
esophageal adenocarcinoma tumors 
were stained with TGM2 antibody as 
described in materials and methods 
and shown here at 10× magnification. 
TGM2 expression is absent in normal 
esophageal squamous epithelium 
(A), Barrett’s esophagus shows only 
low-level expression in stroma (B), and 
higher expression is seen in EACs (C 
and D), respectively.
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before operation. As shown in Fig. 4, four of 21 (19%) of the 
neoadjuvantly resistant EAC specimens had TGM2 overex-
pression compared with known TGM2 amplified and thus the 
highest TGM2 expressing EACs.
TGM2 Knockdown Using siRNA 
Desensitizes EAC Cells to Cisplatin
To determine whether TGM2 expression influ-
ences responsiveness of EAC lines to cisplatin, a first-line 
FIGURE 3.  Amplification of the chromosomal 20q arm is associated with increased TGM2 expression in EACs. A) Amplification 
of individual chromosomal regions in 73 EACs was examined by single nucleotide polymorphism (SNP) array analysis and visual-
ized using hg18 genome build data and IGV software. Increased DNA copy number is shown in red and reduced copy number 
in blue. (B) Magnified view of chromosome 20 where the y-axis shows a descending log2 copy number ratio. Horizontal bars 
represent individual tumor samples. TGM2 is highlighted by a red line at 20q12 and the magnified 82 kb region of the TGM2 
gene is on the right. (C) Copy number of TGM2 from SNP array where 16 of 73 (22%) EACs show doubling of copy number 
with the cutoff value at ≥ 1.8 and representing greater than 4N of the haploid genome. (D) qPCR analysis of intron 2 (gray) and 
intron 11 (black) was performed to determine the TGM2 copy number in 52 EACs. Data were normalized to normal tissue using 
the 2-∆∆Ct algorithm. Highlighted samples are those demonstrating greater than a 1.8-fold increase in TGM2 DNA copy number. 
The frequency of tumors showing copy number increases using the intron 2 probe was eight of 52 (15%) and six of 52 (11.5%) 
with intron 11, with an average of 13.4%. (E) Correlation coefficient of TGM2 intron 11 and intron 2 copy number analyzed 
within the same tumors reveals an r value of 0.96 (p < 0.001).
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chemotherapy agent used for treatment of EAC, we evalu-
ated whether siRNA inhibition of TGM2 altered cell via-
bility. Treatment of both OE19 and OE33 EAC cells with 
TGM2 siRNA for 24 hours effectively knocked down TGM2 
protein levels (Fig. 5A). We observed that siRNA knock-
down significantly decreased cell viability in OE33 (high 
baseline TGM2 expression) when compared with nontarget-
ing siRNA (Fig. 5B). This suggests that TGM2 overexpres-
sion affects cellular proliferation. When OE33 cells were 
treated with cisplatin in addition to siRNA knockdown of 
TGM2, cellular viability increased significantly when com-
pared with mock-transfected cultures at each level of cis-
platin concentration tested (Supplementary Figure 4, SDC 
1, http://links.lww.com/JTO/A609). No effect was evident 
in similar experiments using OE19 (low baseline TGM2 
expression) cells (Data not shown). Further studies are nec-
essary to determine whether screening EAC patients for 
tumor TGM2 levels may help determine chemotherapy regi-
men efficacy.
DISCUSSION
Esophageal cancer is thought to progress from non-dys-
plastic Barrett’s metaplasia to LGD and HGD before devel-
oping into esophageal adenocarcinoma (EAC). Detection of 
cancer before metastatic dissemination is critical for signifi-
cantly improving patient survival.5 Our recent analyses indi-
cate that EAC often contain many single base pair mutations 
yet most occur at relatively low frequency making mutation-
based detection of cancer challenging.40 Identification of 
highly expressed cell surface markers that can be targeted 
using fluorescently labeled and endoscopically applied pep-
tides has the potential to facilitate early detection of EAC.6
TGM2 is a functionally diverse molecule that acts 
either by crosslinking or by binding GTP to mediate signal 
transduction.11 Increased expression of TGM2 is reported to 
be a negative prognostic marker in multiple cancers.19–22,43 
Although a relationship to patient outcome was not found 
in our analyses, increased TGM2 was associated with higher 
tumor stage and poor differentiation indicating tumors over-
expressing TGM2 may be more proliferative or aggressive. 
We observed higher TGM2 in EAC showing inflammatory 
and desmoplastic response (Table 1) and thus may be influ-
enced by these processes. Our qRT-PCR analyses and TMA-
immunohistochemistry confirm that a large percentage of 
EAC that are both associated with BE and those occurring 
at the GEJ without BE demonstrate TGM2 overexpression. 
Further the metaplastic and dysplastic BE show much lower 
expression strongly supporting that this may represent a 
potential marker for early detection in these cancers.
We examined potential reasons for elevated expression 
of TGM2 in EAC in this study. We find that both major iso-
forms of TGM2 are overexpressed in these tumors and thus 
differential isoform expression is unlikely the basis for over-
expression. Similarly, treatment of EAC cell lines with the 
DNA demethylation inhibitor, 5′-aza-2′-deoxycytidine and 
histone deacetylation inhibitor trichostatin A, had minimal 
influence on expression of this gene suggesting it is not mainly 
because of alterations in methylation or histone deacetylation. 
We did find using SNP array-based methods that TGM2 is 
located in a chromosomal region demonstrating gene amplifi-
cation in EAC as we have previously published.44 TGM2 gene 
FIGURE 4.  Chemoresistant esophageal adenocarcinoma 
(EAC) tumors express elevated TGM2. qRT-PCR analysis 
of TGM2 expression in 21 EAC tumors that had minimal 
response to neoadjuvant chemoradiation treatment at the 
time of surgery. The y-axis represents the fold change in 
TGM2 expression relative to the average of normal esophagus 
tissues (N). Among the neoadjuvant-treated patients, four of 
21 (19%) had greater than or equal to twofold greater TGM2 
expression (p < 0.001 by Student’s t test) than two EACs 
demonstrating TGM2 gene amplification and not receiving 
neoadjuvant treatment (EAC).
FIGURE 5.  TGM2 small interfering RNA (siRNA)-mediated knockdown reduces cell viability in esophageal adenocarcinoma 
(EAC) cells. A) OE33 EAC cells were transfected with either nontarget (NT) or 10pM TGM2 siRNA (siTGM2) for 24 hours. Total 
cell lysates were collected and used for western blot analysis of TGM2 and the loading control β–actin (ACTB). Second individual 
siRNAs showed similar TGM2 knockdown efficiency marked with an asterisk. (B) WST-1 assays performed in quadruplicate and 
normalized to the mock control of transfected OE33 with 10pM siRNA of nontarget or TGM2 were measured at 24, 48, and 72 
hours. Student’s t test p values are marked when significant.
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amplification was validated using qPCR of the EACs exam-
ined by SNP array. Because not all tumors that overexpress 
TGM2 showed high gene copy number, other transcriptional 
or posttranslational mechanisms may be involved in the regu-
lation of TGM2 expression in these cancers.
TGM2 may play an important role in chemoresistance 
and has been considered a potentially novel therapeutic target 
for the treatment of resistant tumors.25,38,45 In non–small-cell 
lung adenocarcinoma cell lines, higher TGM2 was associ-
ated with chemoresistance to cisplatin and doxorubicin.46 
Analyses of mRNA levels using microarray drug-sensitive 
cancer cell lines show a correlation between TGM2 gene 
expression and drug resistance to cisplatin.47,48 Dysregulation 
of TGFβ expression has been observed in cancer progres-
sion.29 We noted increased TGFβ expression and found it 
capable of inducing TGM2 expression in lower expressing 
TGM2 esophageal cancer cell lines (Supplementary Figure 
3, SDC 1, http://links.lww.com/JTO/A609). Similarly, we 
observed an increase in TGM2 expression in the “resistant” 
EAC tumors after neoadjuvant treatment with chemotherapy/
radiation. We hypothesized that TGM2 knockdown or enzy-
matic inhibition may sensitize or lead to drug-induced apopto-
sis in resistant tumors; however, the opposite was observed in 
OE33 cells (Supplementary Figure 4, SDC 1, http://links.lww.
com/JTO/A609) and may not reflect accurately the complex-
ity of tumor biology. Because TGM2 knockdown reduced cell 
growth, it is possible that cisplatin that has high cytotoxicity 
in S phase was less effective in reducing cell viability when 
TGM2 is reduced. Although, there are several small TGM2 
molecular inhibitors available, such as the irreversible inhibi-
tors KCC009 and KCA75 that have been shown to sensitize 
lung and glioblastoma cancer cells,25,49,50 none are currently in 
clinical cancer trials.
In summary, we have identified TGM2 as a possible cell 
surface marker overexpressed at the mRNA and protein level 
in EAC with potential for use in early cancer detection. We 
found that TGM2 was highly expressed in EAC patients com-
pared with non-dysplastic BE or BE with dysplasia. Increased 
expression of TGM2 is detected in greater than 65% of EACs 
and increased gene copy number is one mechanism underlying 
its overexpression. We identified the preference of the TGM2 
long isoform in GEJ tumors although the implications of this 
finding are currently unknown. Consistent with the potential 
role of TGM2 as a mediator of chemoresistance,16,38,45,46 ele-
vated TGM2 was noted among tumors obtained from patients 
who had no evidence of a significant pathologic response after 
receiving neoadjuvant treatment with chemotherapy and radi-
ation. This indicates that TGM2 overexpression in EAC may 
have potential as a marker for early detection and for predic-
tion of treatment resistance to current cisplatin-based treat-
ment regimens.
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